ANALGESIA MADE EASY WITH ETHIQA XR®
Get up to 3 Days of Post-Procedural Pain Relief with 1 Pharmaceutical Grade Dose.
Ethiqa XR® (buprenorphine extended-release injectable suspension) 1.3 mg/mL Clll from Fidelis Animal Health, Inc. is the only commercial pharmaceutical-grade extended-release buprenorphine FDA-indexed for the control of post-procedural pain in mice and rats up to 72 hours after just one injection. See efficacy and safety.
Backed by research conducted at John Hopkins University.
An Ethical Imperative Effective pain management for laboratory animals is an essential need in today’s research. Learn more about industry association guidelines.
- Fidelis Animal Health is deeply committed to improving animal welfare with innovative solutions for laboratory animals.
- The Fidelis leadership team supports the foremost veterinary, laboratory research, and human healthcare industry associations and initiatives.
Fidelis Animal Health is a Proud member of the American Association for Laboratory Animal Sciences
Boxed Warning
WARNING: ABUSE POTENTIAL and LIFE-THREATENING RESPIRATORY DEPRESSION and ACCIDENTAL EXPOSURE
Abuse Potential
Ethiqa XR contains buprenorphine, a high-concentration (1.3 mg/mL) opioid agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. The high concentration may be a particular target for human abuse. Buprenorphine has opioid properties that in humans may lead to dependence of the morphine type. Abuse of buprenorphine may lead to low or moderate physical dependence or high psychological dependence. The risk of abuse by humans should be considered when storing, administering, and disposing of Ethiqa XR. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (suicidal depression). Because of human safety risks, this drug should be used only with veterinary supervision.
Do not dispense Ethiqa XR.
Life-Threatening Respiratory Depression
The concentration of buprenorphine in Ethiqa XR is 1.3 mg/mL. Respiratory depression, including fatal cases, may occur with abuse of Ethiqa XR. Ethiqa XR has additive CNS depressant effects when used with alcohol, other opioids, or illicit drugs that cause central nervous system depression. Because of the potential for adverse reactions associated with accidental injection, Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids.
Important Safety Information
For Rats and Mice:
Only administer Ethiqa XR by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use on mice or rats with pre-existing respiratory deficiencies. Do not keep rats on wood chip-type bedding after administration of Ethiqa XR. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression.
For Humans:
Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids. Protective clothing is recommended to avoid direct contact with human skin or mucus membranes which could result in absorption of buprenorphine and adverse reactions. Not for use in humans.
For more information, consult the prescribing information including the boxed warning.